Yazar "Mulayim, Mehmet Kamil" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The Effects of COVID-19 on Psoriasis Patients Using Biologic Treatment: Two-Center Retrospective Study
    (2022) Kuş, Mine Müjde; Ozturk, Perihan; Güner, Mehmet Enes; Nazik, Hulya; Mulayim, Mehmet Kamil; Doğramacı, Asena Çiğdem; Bozkurt, Yemliha
    Objective: The aim of our study is to evaluate the status\rof continuation of treatment of our patients who received biologic treatment\rduring the pandemic and how they were affected by coronavirus\rdisease-2019 (COVID-19). Material and Methods: The clinical processes\rof patients with moderate-severe plaque psoriasis who were\rtreated with biologics between March 2020 and February 2021 were\revaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients\rwho received biologic therapy stopped treatment at the beginning of\rthe pandemic. Fourteen of the 123 patients who were continuing the\rtreatment were positive for COVID-19. One of the 33 psoriasis patients\rwho stopped biologic treatment was positive for COVID-19. There was\rno statistical difference between those who continued with biologic\rtreatment and those who did not in the rates of positivity for COVID-\r19 after contact with a COVID-19 positive person, and frequency of\rsevere symptoms (p=0.607, p=1.00, respectively). In terms of the difference\rbetween the mean of Psoriasis Area Severity Index (PASI)\rscores at the onset of the pandemic and the mean of PASI scores at the\r12th month, there was no statistical difference between those who were\rpositive for COVID-19 and those who did not (p=0.782). Conclusion:\rWe have observed that the treatment with biologic agents in psoriasis\rpatients does not increase the COVID-19 transmission risk, does not\rcause severe disease, and does not increase the hospitalization rate and\rmortality rate.
  • [ N/A ]
    Öğe
    The Effects of COVID-19 on Psoriasis Patients Using Biologic Treatment: Two-Center Retrospective Study
    (OrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S., 2022) Kus, Mine Mujde; Ozturk, Perihan; Dogramaci, Asena Cigdem; Guner, Mehmet Enes; Bozkurt, Yemliha; Nazik, Hulya; Mulayim, Mehmet Kamil
    Objective: The aim of our study is to evaluate the status of continuation of treatment of our patients who received biologic treatment during the pandemic and how they were affected by coronavirus disease-2019 (COVID-19). Material and Methods: The clinical processes of patients with moderate-severe plaque psoriasis who were treated with biologics between March 2020 and February 2021 were evaluated. Results: Thirty-three (21.2%) of our 156 psoriasis patients who received biologic therapy stopped treatment at the beginning of the pandemic. Fourteen of the 123 patients who were continuing the treatment were positive for COVID-19. One of the 33 psoriasis patients who stopped biologic treatment was positive for COVID-19. There was no statistical difference between those who continued with biologic treatment and those who did not in the rates of positivity for COVID- 19 after contact with a COVID-19 positive person, and frequency of severe symptoms (p=0.607, p=1.00, respectively). In terms of the difference between the mean of Psoriasis Area Severity Index (PASI) scores at the onset of the pandemic and the mean of PASI scores at the 12th month, there was no statistical difference between those who were positive for COVID-19 and those who did not (p=0.782). Conclusion: We have observed that the treatment with biologic agents in psoriasis patients does not increase the COVID-19 transmission risk, does not cause severe disease, and does not increase the hospitalization rate and mortality rate. © 2022 OrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.. All rights reserved.